 SAN FRANCISCO, Jan. 5, 2021 PRNewswire -- Nektar Therapeutics NASDAQ: NKTR announced today that it has appointed Brian Kotzin, MD as Interim Chief Medical Officer, Head of Development effective immediately. Since 2017, Dr. Kotzin has served as Senior Vice President, Clinical... 